Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Leases: 2023-2025

Historic Operating Leases for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $425,000.

  • Tonix Pharmaceuticals Holding's Operating Leases fell 39.29% to $425,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $425,000, marking a year-over-year decrease of 39.29%. This contributed to the annual value of $358,000 for FY2024, which is 43.35% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Operating Leases is $425,000, which was down 13.62% from $492,000 recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Operating Leases registered a high of $898,000 during Q2 2023, and its lowest value of $358,000 during Q4 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Operating Leases value was $632,000 (recorded in 2023), while the average stood at $645,818.
  • Data for Tonix Pharmaceuticals Holding's Operating Leases shows a peak YoY increase of 59.09% (in 2024) and a maximum YoY decrease of 43.35% (in 2024) over the last 5 years.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Operating Leases (Quarterly) stood at $632,000 in 2023, then crashed by 43.35% to $358,000 in 2024, then plummeted by 39.29% to $425,000 in 2025.
  • Its last three reported values are $425,000 in Q3 2025, $492,000 for Q2 2025, and $563,000 during Q1 2025.